Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis

BACKGROUND: Peficitinib (ASP015K), a novel oral Janus kinase inhibitor, has demonstrated efficacy and safety in the treatment of patients with rheumatoid arthritis (RA). This study evaluated the effect of peficitinib on patient- and physician-reported outcomes in Asian patients with RA and an inadeq...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yoshiya, Takeuchi, Tsutomu, Izutsu, Hiroyuki, Kaneko, Yuichiro, Kato, Daisuke, Fukuda, Musashi, Rokuda, Mitsuhiro, Schultz, Neil M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383363/
https://www.ncbi.nlm.nih.gov/pubmed/34429152
http://dx.doi.org/10.1186/s13075-021-02590-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383363/
https://www.ncbi.nlm.nih.gov/pubmed/34429152
http://dx.doi.org/10.1186/s13075-021-02590-z

Ejemplares similares